Lung cancer chemoprevention: Current status and future prospects

Nature Reviews Clinical Oncology

Volumn 10, Issue 6, 2013, Pages 334-343

  Keith, Robert L ^a   Miller, York E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANETHOLE TRITHIONE; BETA CAROTENE; BUDESONIDE; CELECOXIB; CORTICOSTEROID; CYANOCOBALAMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETRETINATE; FENRETINIDE; FLUTICASONE; FOLIC ACID; FULVESTRANT; ILOPROST; INDOMETACIN; INOSITOL; ISOTRETINOIN; KI 67 ANTIGEN; MULTIVITAMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PROSTACYCLIN; PROTEIN P53; RETINOL PALMITATE; SELENIUM; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER; UNINDEXED DRUG; VANDETANIB;

ANTIANGIOGENIC ACTIVITY; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CANCER CLASSIFICATION; CANCER CONTROL; CANCER GRADING; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CAUSE OF DEATH; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COMORBIDITY; DIABETES MELLITUS; DRUG RESEARCH; EGFR GENE; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; EPITHELIUM CELL; GENE MUTATION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HIGH RISK POPULATION; HISTOLOGY; HUMAN; IMMUNOSURVEILLANCE; KRAS GENE; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALIGNANT NEOPLASTIC DISEASE; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; NONHUMAN; OBSERVATIONAL STUDY; ONCOGENE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PRECANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; SOX2 GENE; TP63 GENE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR INVASION; VALIDATION PROCESS; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS;

EID: 84878606415     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.64     Document Type: Review

References (127)

1. Sporn, M. B. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 36, 2699-2702 (1976).
2. Spitz, M. R. et al. A risk model for prediction of lung cancer. J. Natl Cancer Inst. 99, 715-726 (2007).
3. Bach, P. B. et al. Variations in lung cancer risk among smokers. J. Natl Cancer Inst. 95, 470-478 (2003).
4. Anthonisen, N. R. et al. The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial. Ann. Intern. Med. 142, 233-239 (2005).
5. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
6. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
7. National Lung Screening Trial Research Team et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395-409 (2011).
8. Johnson, B. E. Second lung cancers in patients after treatment for an initial lung cancer. J. Natl Cancer Inst. 90, 1335-1345 (1998).
9. Spitz, M. R. et al. An expanded risk prediction model for lung cancer. Cancer Prev. Res. (Phila.) 1, 250-254 (2008).
10. The Health Consequences of Smoking: A Report of the Surgeon General. Office of the Surgeon General (US); Office on Smoking and Health (US). Atlanta (GA): Centers for Disease Control and Prevention (US) [online], http://www.surgeongeneral.gov/library/reports/smokingconsequences/index.html (2004).
11. Jha, P. et al. 21st-century hazards of smoking and benefits of cessation in the United States. N. Engl. J. Med. 368, 341-350 (2013).
12. Pirie, K. et al. The 21st century hazards of smoking and benefits of stopping: A prospective study of one million women in the UK. Lancet 381, 133-141 (2012).
13. Tong, L., Spitz, M. R., Fueger, J. J. & Amos, C. A. Lung carcinoma in former smokers. Cancer 78, 1004-1010 (1996).
14. Halpern, M. T., Gillespie, B. W. & Warner, K. E. Patterns of absolute risk of lung cancer mortality in former smokers. J. Natl Cancer Inst. 85, 457-464 (1993).
15. Hennekens, C. H. et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334, 1145-1149 (1996).
16. Omenn, G. S. et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J. Natl Cancer Inst. 88, 1550-1559 (1996).
17. Lockwood, W. W. et al. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS ONE 7, e37775 (2012).
18. Nicholson, A. G. et al. Reproducibility of the WHO/IASLC grading system for pre-invasive squamous lesions of the bronchus: A study of inter-observer and intra-observer variation. Histopathology 38, 202-208 (2001).
19. Jonsson, S. et al. Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. Am. J. Respir. Crit. Care Med. 177, 342-347 (2008).
20. Salaun, M. et al. Molecular predictive factors for progression of high-grade preinvasive bronchial lesions. Am. J. Respir. Crit. Care Med. 177, 880-886 (2008).
21. van Boerdonk, R. A. et al. DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer. Am. J. Respir. Crit. Care Med. 184, 948-956 (2011).
22. Franklin, W. A. et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J. Clin. Invest. 100, 2133-2137 (1997).
23. Wistuba, I. I. et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18, 643-650 (1999).
24. McCaughan, F. et al. Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am. J. Respir. Crit. Care Med. 182, 83-91 (2010).
25. Travis, W. D. et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: The clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J. Thorac. Oncol. 1, S13-S19 (2006).
26. Tang, X. et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 65, 7568-7572 (2005).
27. Meert, A. P. et al. Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions. Eur. Respir. J. 21, 611-615 (2003).
28. Soh, J. et al. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J. Thorac. Oncol. 3, 340-347 (2008).
29. Slaughter, D. P., Southwick, H. W. & Smejkal, W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6, 963-968 (1953).
30. Rusch, V., Klimstra, D., Linkov, I. & Dmitrovsky, E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res. 55, 1365-1372 (1995).
31. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
32. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
33. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
34. Veronesi, G. et al. Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev. Res. (Phila.) 4, 34-42 (2011).
35. Lam, S. et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin. Cancer Res. 10, 6502-6511 (2004).
36. van den Berg, R. M. et al. CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. Lung Cancer 60, 57-61 (2008).
37. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N. Engl. J. Med. 32, 129-135 (1989).
38. Cook, N. R. et al. Low-dose aspirin in the primary prevention of cancer: The Women's Health Study: A randomized controlled trial. JAMA 294, 47-55 (2005).
39. Peto, R. et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br. Med. J. (Clin. Res. Ed.) 296, 313-316 (1988).
40. van Zandwijk, N., Dalesio, O., Pastorino, U., de Vries, N. & van Tinteren, H. EUROSCAN, a randomized trial of vitamin A and N acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J. Natl Cancer Inst. 92, 977-986 (2000).
41. Lippman, S. M. et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non small cell lung cancer. J. Natl Cancer Inst. 93, 605-618 (2001).
42. Blumberg, J. & Block, G. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study in Finland. Nutr. Rev. 52, 242-245 (1994).
43. Slatore, C. G., Littman, A. J., Au, D. H., Satia, J. A. & White, E. Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. Am. J. Respir. Crit. Care Med. 177, 524-530 (2008).
44. Karp, D. D. et al. A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 18 (Suppl.), CRA7004 (2010).
45. Kelly, R. J., Lopez-Chavez, A. & Szabo, E. Criteria of evidence to move potential chemopreventive agents into late phase clinical trials. Curr. Drug Targets 12, 1983-1988 (2011).
46. Keith, R. L. & Miller, Y. E. Lung cancer: Genetics of risk and advances in chemoprevention. Curr. Opin. Pulm. Med. 11, 265-271 (2005).
47. Prentice, R. L. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat. Med. 8, 431-440 (1989).
48. Miller, Y. E. et al. Bronchial epithelial Ki 67 index is related to histology, smoking, and gender, but not lung cancer or chronic obstructive pulmonary disease. Cancer Epidemiol. Biomarkers Prev. 16, 2425-2431 (2007).
49. Spira, A. et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc. Natl Acad. Sci. USA 101, 10143-10148 (2004).
50. Spira, A. et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat. Med. 13, 361-366 (2007).
51. Rahman, S. M. et al. Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res. 71, 3009-3017 (2011).
52. Ostroff, R. M. et al. Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS ONE 5, e15003 (2010).
53. Peled, N. et al. Non-invasive breath analysis of pulmonary nodules. J. Thorac. Oncol. 7, 1528-1533 (2012).
54. Kelly, K. et al. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev. Res. (Phila.) 2, 440-449 (2009).
55. Lee, J. S. et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J. Clin. Oncol. 12, 937-945 (1994).
56. Keith, R. L. et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev. Res. (Phila.) 4, 793-802 (2011).
57. Kim, E. S. et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev. Res. (Phila.) 3, 148-159 (2010).
58. Mao, J. T. et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev. Res. (Phila.) 4, 984-993 (2011).
59. Chang, B. et al. Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan. Chest 143, 172-178 (2013).
60. Lam, S. et al. A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol. Biomarkers Prev. 15, 1526-1531 (2006).
61. Gustafson, A. M. et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci. Transl. Med. 2, 26ra25 (2010).
62. Malkinson, A. M., Koski, K. M., Evans, W. A. & Festing, M. F. Butylated hydroxytoluene exposure is necessary to induce lung tumors in BALB mice treated with 3 methylcholanthrene. Cancer Res. 57, 2832-2824 (1997).
63. Johnson, L. et al. Somatic activation of the K ras oncogene causes early onset lung cancer in mice. Nature 410, 1111-1116 (2001).
64. Regales, L. et al. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2, e810 (2007).
65. Fisher, G. H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249-3262 (2001).
66. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K ras. Genes Dev. 15, 3243-3248 (2001).
67. Mirvish, S. S. The carcinogenic action and metabolism of urethan and N hydroxyurethan. Adv. Cancer Res. 1, 1-42 (1968).
68. Witschi, H. Tobacco smoke as a mouse lung carcinogen. Exp. Lung Res. 24, 385-394 (1998).
69. Wang, Y. et al. A chemically induced model for squamous cell carcinoma of the lung in mice: Histopathology and strain susceptibility. Cancer Res. 64, 1647-1654 (2004).
70. Hudish, T. M. et al. N nitroso tris-chloroethylurea induces premalignant squamous dysplasia in mice. Cancer Prev. Res. (Phila.) 5, 283-289 (2012).
71. Stearman, R. S. et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am. J. Pathol. 167, 1763-1775 (2005).
72. Wang, D. & DuBois, R. N. Eicosanoids and cancer. Nat. Rev. Cancer 10, 181-193 (2010).
73. Vane, J. R. Prostacyclin: A hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981. J. Endocrinol. 95, 3P-43P (1982).
74. Nemenoff, R. et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma. Cancer Prev. Res. (Phila.) 1, 349-356 (2008).
75. Chang, T. H. & Szabo, E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res. 60, 1129-1138 (2000).
76. Keshamouni, V. G. et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non small cell lung cancer. Oncogene 23, 100-108 (2004).
77. Lyon, C. M. et al. Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis 30, 2095-2099 (2009).
78. Wang, Y. et al. Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. Mol. Cancer Ther. 9, 3074-3082 (2010).
79. Fu, H. et al. Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice. Mol. Carcinog. 50, 913-921 (2011).
80. Wattenberg, L. W. et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 21, 179-182 (2000).
81. Keith, R. L. et al. Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res. 62, 734-740 (2002).
82. Karoor, V., Le, M., Merrick, D., Dempsey, E. C. & Miller, Y. E. Vascular endothelial growth factor receptor 2 targeted chemoprevention of murine lung tumors. Cancer Prev. Res. (Phila.) 3, 1141-1147 (2010).
83. Stabile, L. P. et al. Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. Carcinogenesis 33, 2181-2189 (2012).
84. Moody, T. W. et al. Indomethacin reduces lung adenoma number in A/J mice. Anticancer Res. 21, 1749-1755 (2001).
85. Kisley, L. R. et al. Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 23, 1653-1660 (2002).
86. Liby, K. T. & Sporn, M. B. Synthetic oleanane triterpenoids: Multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev. 64, 972-1003 (2012).
87. Liby, K. et al. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol. Cancer Ther. 7, 1251-1257 (2008).
88. Liby, K. et al. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 67, 2414-2419 (2007).
89. Algra, A. M. & Rothwell, P. M. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13, 518-527 (2012).
90. Oh, S. W. et al. Aspirin use and risk for lung cancer: A meta-analysis. Ann. Oncol. 22, 2456-2465 (2011).
91. Rothwell, P. M. et al. Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 377, 31-41 (2011).
92. Parimon, T. et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 712-719 (2007).
93. Govindarajan, R. et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J. Clin. Oncol. 25, 1476-1481 (2007).
94. Mazzone, P. J. et al. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 12, 410 (2012).
95. Ferrara, A. et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 34, 923-929 (2011).
96. Smiechowski, B. B., Azoulay, L., Yin, H., Pollak, M. N. & Suissa, S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 36, 124-129 (2013).
97. Bodmer, M., Becker, C., Jick, S. S. & Meier, C. R. Metformin does not alter the risk of lung cancer: A case-control analysis. Lung Cancer 78, 133-137 (2012).
98. Lai, S. W. et al. Antidiabetes drugs correlate with decreased risk of lung cancer: A population-based observation in Taiwan. Clin. Lung Cancer 13, 143-148 (2012).
99. Noto, H., Goto, A., Tsujimoto, T. & Noda, M. Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS ONE 7, e33411 (2012).
100. Soranna, D. et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-analysis. Oncologist 17, 813-822 (2012).
101. Memmott, R. M. et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev. Res. (Phila.) 3, 1066-1076 (2010).
102. Engelman, J. A. & Cantley, L. C. Chemoprevention meets glucose control. Cancer Prev. Res. (Phila.) 3, 1049-1052 (2010).
103. Siegfried, J. M., Hershberger, P. A. & Stabile, L. P. Estrogen receptor signaling in lung cancer. Semin. Oncol. 36, 524-531 (2009).
104. Ganti, A. K., Sahmoun, A. E., Panwalkar, A. W., Tendulkar, K. K. & Potti, A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J. Clin. Oncol. 24, 59-63 (2006).
105. Chlebowski, R. T. et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J. Natl Cancer Inst. 102, 1413-1421 (2010).
106. Clague, J. et al. Menopausal hormone therapy does not influence lung cancer risk: Results from the California Teachers Study. Cancer Epidemiol. Biomarkers Prev. 20, 560-564 (2011).
107. Brinton, L. A. et al. Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Causes Control 23, 487-496 (2012).
108. Coombes, R. C. et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081-1092 (2004).
109. Goss, P. E. et al. Exemestane for breast-cancer prevention in postmenopausal women. N. Engl. J. Med. 364, 2381-2391 (2011).
110. Key, T. J. Fruit and vegetables and cancer risk. Br. J. Cancer 104, 6-11 (2011).
111. Young, R. P. et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur. Respir. J. 34, 380-386 (2009).
112. Burge, P. S. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 320, 1297-1303 (2000).
113. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 343, 1902-1909 (2000).
114. Vestbo, J. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 353, 1819-1823 (1999).
115. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00780234 (2013).
116. Gupta, R. A. et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl Acad. Sci. USA 97, 13275-13280 (2000).
117. Alvarez-Calderon, F., Gregory, M. A. & Degregori, J. Using functional genomics to overcome therapeutic resistance in hematological malignancies. Immunol. Res. 55, 100-115 (2013).
118. Wang, D. L. et al. Topical delivery of 13 cis retinoic acid by inhalation up-regulates expression of rodent lung but not liver retinoic acid receptors. Clin. Cancer Res. 6, 3636-3645 (2000).
119. Mendez, L. B., Gookin, G. & Phalen, R. F. Inhaled aerosol particle dosimetry in mice: A review. Inhal. Toxicol. 22, 1032-1037 (2010).
120. Keith, R. L. et al. Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin. Cancer Res. 6, 1616-1625 (2000).
121. Karoor, V. et al. Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism. Cancer Prev. Res. (Phila.) 5, 1061-1071 (2012).
122. Omenn, G. S. et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334, 1150-1155 (1996).
123. Kurie, J. M. et al. N (4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin. Cancer Res. 6, 2973-2979 (2000).
124. Arnold, A. M. et al. The effect of the synthetic retinoid etretinate on sputum cytology: Results from a randomised trial. Br. J. Cancer 65, 737-743 (1992).
125. McLarty, J. W. et al. Beta-carotene, vitamin A, and lung cancer chemoprevention: Results of an intermediate endpoint study. Am. J. Clin. Nutr. 62, 1431S-1438S (1995).
126. Heimburger, D. C. et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. JAMA 259, 1525-3150 (1988).
127. Lam, S. et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J. Natl Cancer Inst. 94, 1001-1009 (2002).